{
    "organizations": [],
    "uuid": "878a91de05480a79ebddbcd0928ef1e12d6933fc",
    "author": "cnbc.com",
    "url": "http://www.cnbc.com/2018/05/08/pr-newswire-brainstorm-to-announce-first-quarter-financial-results-and-provide-corporate-update-on-monday-may-14.html",
    "ord_in_thread": 0,
    "title": "Brainstorm to Announce First Quarter Financial Results and Provide Corporate Update on Monday, May 14",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "NEW YORK and PETACH TIKVAH, Israel, May 8, 2018 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, will hold a conference call to discuss its financial results for the first , and provide important corporate updates, on Monday, May 14 at 8:30am Eastern Time.\nMonday, May 14, 2018 @ 8:30am Eastern Time\nUSA Toll Free:\n800-239-9838\nUSA & International Investors:\n323-794-2551\nIsrael Investors:\n1809 212 883\nConference ID:\n6273879\nWebcast:\nhttps://goo.gl/nNMzYw\nReplays, available through May 28th, 2018\nToll Free:\n844-512-2921\nInternational:\n412-317-6671\nConference ID:\n6273879\nWebcast:\nhttps://goo.gl/nNMzYw\nAbout BrainStorm Cell Therapeutics Inc .\nBrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwnÂ® technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. NurOwn has been administered to approximately 75 patients with ALS in clinical trials conducted in the United States and Israel. In a randomized, double-blind, placebo-controlled clinical trial conducted in the U. S., a clinically meaningful benefit was demonstrated by higher response to NurOwn compared with placebo. For more information, visit the company's website at www.brainstorm-cell.com .\nCONTACTS\nMedia:\nUri Yablonka\nChief Business Officer\nBrainstorm Cell Therapeutics Inc.\nPhone: (646) 666-3188\nuri@brainstorm-cell.com\nInvestors:\nMichael Rice\nLifeSci Advisors, LLC\nPhone: 646-597-6979\nmrice@lifesciadvisors.com\nView original content with multimedia: http://www.prnewswire.com/news-releases/brainstorm-to-announce-first-quarter-financial-results-and-provide-corporate-update-on-monday-may-14-300644413.html\nSOURCE BrainStorm Cell Therapeutics Inc.",
    "published": "2018-05-08T15:12:00.000+03:00",
    "crawled": "2018-05-08T17:12:57.000+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "new",
        "york",
        "petach",
        "tikvah",
        "israel",
        "may",
        "brainstorm",
        "cell",
        "therapeutic",
        "nasdaq",
        "bcli",
        "leading",
        "developer",
        "adult",
        "stem",
        "cell",
        "technology",
        "neurodegenerative",
        "disease",
        "hold",
        "conference",
        "call",
        "discus",
        "financial",
        "result",
        "first",
        "provide",
        "important",
        "corporate",
        "update",
        "monday",
        "may",
        "eastern",
        "time",
        "monday",
        "may",
        "eastern",
        "time",
        "usa",
        "toll",
        "free",
        "usa",
        "international",
        "investor",
        "israel",
        "investor",
        "conference",
        "id",
        "webcast",
        "http",
        "replay",
        "available",
        "may",
        "28th",
        "toll",
        "free",
        "international",
        "conference",
        "id",
        "webcast",
        "http",
        "brainstorm",
        "cell",
        "therapeutic",
        "inc",
        "brainstorm",
        "cell",
        "therapeutic",
        "biotechnology",
        "company",
        "engaged",
        "development",
        "adult",
        "stem",
        "cell",
        "therapy",
        "derived",
        "autologous",
        "bone",
        "marrow",
        "cell",
        "treatment",
        "neurodegenerative",
        "disease",
        "company",
        "hold",
        "right",
        "develop",
        "commercialize",
        "technology",
        "exclusive",
        "worldwide",
        "licensing",
        "agreement",
        "ramot",
        "technology",
        "transfer",
        "company",
        "tel",
        "aviv",
        "university",
        "nurown",
        "administered",
        "approximately",
        "patient",
        "al",
        "clinical",
        "trial",
        "conducted",
        "united",
        "state",
        "israel",
        "randomized",
        "clinical",
        "trial",
        "conducted",
        "clinically",
        "meaningful",
        "benefit",
        "demonstrated",
        "higher",
        "response",
        "nurown",
        "compared",
        "placebo",
        "information",
        "visit",
        "company",
        "website",
        "contact",
        "medium",
        "uri",
        "yablonka",
        "chief",
        "business",
        "officer",
        "brainstorm",
        "cell",
        "therapeutic",
        "phone",
        "uri",
        "investor",
        "michael",
        "rice",
        "lifesci",
        "advisor",
        "llc",
        "phone",
        "mrice",
        "view",
        "original",
        "content",
        "multimedia",
        "http",
        "source",
        "brainstorm",
        "cell",
        "therapeutic",
        "inc"
    ]
}